Spero Therapeutics, Inc. (SPRO) trades at a trailing P/E of 17.9, forward P/E of 4.2. Trailing earnings yield is 5.59%, forward earnings yield 24.10%. PEG 0.01 (Peter Lynch undervalued ≤1.0). Graham Number is $1.90.
Criteria proven by this page:
Overall SharesGrow Score: 61/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -3.0 | -0.02 | 7.47 | 226.73 | - |
| 2017 | -0.7 | 0.00 | 0.36 | 15.36 | - |
| 2018 | -2.4 | 0.03 | 0.85 | 24.81 | - |
| 2019 | -2.9 | -0.11 | 2.34 | 9.63 | - |
| 2020 | -5.5 | -0.87 | 3.29 | 46.52 | - |
| 2021 | -5.5 | 0.32 | 5.60 | 161.12 | - |
| 2022 | -1.4 | 0.02 | 0.86 | 1.34 | - |
| 2023 | 3.4 | -0.03 | 0.72 | 0.75 | - |
| 2024 | -0.8 | 0.00 | 1.21 | 1.16 | - |
| 2025 | 15.2 | -0.14 | 2.21 | 2.19 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-3.86 | $335K | $-25.49M | -7609.3% |
| 2017 | $-17.82 | $1.98M | $-46.1M | -2329.3% |
| 2018 | $-2.60 | $3.97M | $-41.66M | -1050.5% |
| 2019 | $-3.31 | $4.74M | $-60.18M | -1269% |
| 2020 | $-3.46 | $9.33M | $-77.52M | -830.9% |
| 2021 | $-2.96 | $18.26M | $-91.3M | -500.1% |
| 2022 | $-1.28 | $48.58M | $-48.03M | -98.9% |
| 2023 | $0.43 | $96.74M | $22.81M | 23.6% |
| 2024 | $-1.27 | $27.4M | $-68.57M | -250.3% |
| 2025 | $0.15 | $59.62M | $8.57M | 14.4% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $0.67 | $0.67 – $0.67 | $800K | $800K – $800K | 1 |
| 2027 | $-0.68 | $-0.68 – $-0.68 | $3.2M | $3.2M – $3.2M | 1 |
| 2028 | $-0.12 | $-0.12 – $-0.12 | $33.1M | $33.1M – $33.1M | 1 |
| 2029 | $0.75 | $0.75 – $0.75 | $99.1M | $99.1M – $99.1M | 1 |
